-
1.发明公开公开(公告)号：US20240123034A1
公开(公告)日：2024-04-18
申请号：US17768514
申请日：2020-10-15
发明人： Eric Yi-Chun Huang , Jared Iacovelli , Seymour De Picciotto , Sze-Wah Tse , Laurie Kenney , Katherine Olson , Howard Gendelman , Lee R. Mosley
IPC分类号： A61K38/19 , A61K9/51 , A61K31/7115 , A61P25/16
CPC分类号： A61K38/193 , A61K9/5123 , A61K31/7115 , A61P25/16
摘要： The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding human GM-CSF for use in such treatment.
-
公开(公告)号：US20230130155A1
公开(公告)日：2023-04-27
申请号：US17759687
申请日：2021-01-29
申请人： ModernaTX, Inc.
IPC分类号： A61K9/51 , A61K31/7105 , B82Y5/00 , A61P37/06
摘要： The disclosure features lipid nanoparticle (LNP) compositions comprising metabolic reprogramming molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding metabolic reprogramming polypeptides, e.g., IDO, TDO, AMPK, AhR, ALDH1A2, HMOX1, CD73 or CD39. The LNP compositions of the present disclosure can reprogram myeloid and/or dendritic cells, suppress T cells and/or induce immune tolerance in vivo.
-
公开(公告)号：US20230112857A1
公开(公告)日：2023-04-13
申请号：US17758520
申请日：2021-01-08
申请人： ModernaTX, Inc.
IPC分类号： A61K48/00 , C12N15/88 , C07K14/705 , A61K9/127 , A61P37/06
摘要： The disclosure features lipid nanoparticle (LNP) compositions comprising immune checkpoint inhibitor molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding immune checkpoint inhibitor polypeptides, e.g., PD-L1, PD-L2, B7-H3, B7-H4, CD200 Galectin 9 and CTLA4. The LNP compositions of the present disclosure can reprogram dendritic cells, suppress T cells and/or induce immune tolerance in vivo.
-
-
搜索结果
3 条记录 (耗时 0.016 秒)
